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ABSTRACT: OBJECTIVE: this prospective study evaluates the feasibility in current clinical prac-
tice of contrast enhanced CT-scan for diagnosis purpose, performed during 18FDG PET-CT study
with a PET/CT tomography. METHOD: 25 patients underwent FDG imaging for lymphoma stag-
ing. The PET scan was done immediately after the usual low dose CT (lCT). A second CT scan
was consequently acquired, by using classical diagnosis CT parameters (dCT) and iodinated con-
trast. For each patient, all CT attenuation correction (CTAC) PET images were visually compared.
Density in Hounsfield units (HU) and maximum Standardized Uptake Value (SUVmax) were then
measured on different organs and up to 5 specific lymphoma localizations (total of 294 measure-
ments). RESULTS: Visual analysis was similar for the 2 modalities, without discordant interpre-
tation for the pathologic sites. SUVmax means and standard deviation of each organ for lCTAC
and dCTAC were comparable. The equation of the fitted multiple linear regression model was:
dCT=0.0748191 + 1.17024*lCT (98.71%; p< 0.01).CONCLUSION: These first results allow the
use of injected CT scan, before the PET scan acquisition for lymphoma staging with this PET-CT
scan, not affected by the height atomic number and elevated density. A great benefit is therefore
obtained on diagnostic, logistic and radioprotection purposes.
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Actually, both CT scan (computed tomography) and PET scan (positron emission tomography)
are required in the staging and follow-up of Hodgkin and non-hodgkin lymphomas [1]. CT scan
provides anatomic structures, and contrast enhanced CT shows vessels, lymph nodes, digestive
structures with a better contrast, thus anatomical diagnosis is more precise. PET scan shows in-
creased intracellular accumulation of 18F-FDG (18 fluorine deoxyglucose), thus providing func-
tional information in terms of high metabolic activity in tumor sites. Contrast enhanced CT scan
is usually performed in radiology units and PETscan in nuclear medicine units. Actually, most
of the cameras are PET/CT cameras and a complete FDG study include a low dose, non injected
CT scan, performed immediately before the PET acquisition, for attenuation correction of the 511
KeV gamma photons and for locating purpose. This system provides fusion imaging, with both
functional parameters given by PET scan and anatomical information given by CT scan.
The aim of this prospective study is to evaluate the feasibility in current clinical practice of
contrast enhanced CT-scan for diagnosis purpose, performed during 18FDG PET-CT study.
2 Method
25 patients (8 males and 17 females, mean age 46± 17 years), underwent 18F-FDG imaging for
lymphoma staging (Hodgkin disease: 8, non Hodgkin lymphomas: 17).Standard activity was intra-
venously administrated one hour before PET examination (5.2 MBq/kg of 18F-FDG) and optimal
condition for glycaemia was verified, (mean blood glucose level: 6.00±1,17 mmoles/L) The cam-
era we used was a GEMINI PET-CT camera PHILIPS MEDICAL SYSTEMS. Low dose for locat-
ing and for attenuation correction CT (lCT) was first realized with usual parameters (120 KeV —
100 mAs — slices 3.2 mm — FOV 600mm — free breathing). Then, 18F-FDG TEP examination
with the same coverage was done immediately after the first lCT scan. A second full dose CT scan
(dCT) with classical diagnosis purpose parameters (120 KeV — 270 to 350 mAs — slices 6 mm —
FOV 600mm) and free breathing with iodinated contrast (100 ml of Iobitridol) was consequently
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Figure 1. No difference for malignancy diagnosis on CTAC images corrected by lCT and dCT — upper:
non metastatic vertebra — lower: metastatic vertebra A: non injected CT — B: injected CT
acquired just after the PET examination [2, 3]. Delay between injection and acquisition was around
45 seconds (venous phase). Dosimetric data were similar than that obtained with diagnosis purpose
CT scan (mean DLP: 998.83±359.96 mGy*cm Range 581.8–1501.5 mGy*cm).
Visual comparison, for each patient, on CTAC PET images, corrected by both lCT and dCT,
was performed by 3 experimented observers (C.H., C.T., I.M.). Density in Hounsfield units (HU)
on CT images and maximum Standardized Uptake Value (SUV max) on both CTAC PET images
were measured by ROI method (regions of interest). Studied regions (number of points of mea-
sure: N = 294) were located on different organs: brain (grey matter, white matter), lung, aorta,
paravertebral muscles, liver, spleen, acetabulum (cortical and medullar bone) and up to 5 specific
localisations depending on the pathology (tumour tissue, lymph nodes. . . ).
3 Results
Visual analysis gave the same results for the 2 modalities, without discordant interpretation for the
pathologic sites (figure 1).
SUVmax means (M) and standard deviation (SD) of each organ for lCTAC and dCTAC PET
images were comparable (table 1). Means for different localisations for each patient were also
similar.
A statistical study (multiple linear regression) was performed for SUVmax values on lCT and
dCT CTAC PET images. Significant relationship between the variables at the 99% confidence level
was found.
The equation of the fitted multiple regression linear model was:
dCT SUV max = 0.0748191+1.17024∗ lCT SUV max
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Table 1. Density in HU and SUVmax means and SD for some organs (G.M.: grey matter; C.B.: cortical
bone) for lCTAC and dCTAC images. Aorta has a low density in HU on lCT images and high density on
dCT images; on lCTAC and dCTAC PET images, no real change was observed for SUVmax.
lung G.M. C.B. aorta
HU mean
lCT -747 48 480 37
dCT -720 79 498 176
SUVmax mean
lCT 0.47 5.48 0.60 1.20
dCT 0.45 6.80 0.38 1.52
SUVmax SD
lCT 0.18 2.19 0.36 0.27
dCT 0.18 2.99 0.33 0.25
Figure 2. Statistic study: means for organs SUVmax — significant relationship between the variables at the
99% confidence level.
(with Adjusted R-squared statistic 98.712% p< 0.01) (figure 2). It means that for SUVmax there
is only a regular increase of 17%, for all different absolute values. Relative values didn’t change;
this fact explains why no change was observed for visual analysis.
4 Discussion
Our results are in accordance with bibliographic data. Rodrı´guez-Vigil et al. [4] performed a
prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT during a
PET/CT examination in lymphoma in 47 patients. They compare results on CTAC images corrected
by injected CT (ICT) and non injected (NICT) on 24 lymph nodes regions and 8 extralymphatic
sites. Less indeterminated data and more pathologic sites were seen with ICT, with a very good
concordance for the staging. Their conclusion was that NICT is sufficient for the initial staging and
ICT has to be reserved for special cases (i.e. dosimetric considerations).
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Figure 3. On CTAC image, false activity measured in the tube with KI solution without real activity inside;
on NAC image, no activity is seen.
Figure 4. No artefact for the KI solution on CTAC image with our camera.
Yau YY et al. studied whether the application of intravenous contrast in PET/CT really intro-
duces significant attenuation correction error [5]. Examinations were performed with a Discovery
GE TEP-TDM on 54 patients, and 193 regions were compared, on CTAC images corrected by
NICT et ICT (Visual analysis and SUVmax on both modalities). Their conclusion was that the
correction by ICT doesn’t increase significantly the SUVmax and visual analysis is not modified.
Similar studies have been already realized using other PET cameras [4–6], but important facts
have to be verified. Phantom studies previously performed [7, 8], demonstrated that attenuation
correction by CT for high atomic number may produce artefact, depending on the camera (3 types
of PET/CT cameras have been experimented). This artefact consists in false activity measures
in tube containing KI solution on the images corrected by CT (CTAC). These abnormal effects
were not seen on the non corrected images (NAC) (figure 3). Enhanced CT scans are performed
with iodinated contrast witch atomic number is 53. The camera we used was a Philips witch
is not affected by high atomic number neither elevated density (figure 4). We could therefore
demonstrate that there is no change for visual analysis and good statistical results for lCTSUVmax.
and dCTSUVmax.
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5 Conclusion
These preliminary results allow the use of intravenously iodinated injected CT scan, before the
PET scan acquisition with this PET-CT camera, for lymphoma staging.
A great benefit is therefore obtained on different purposes:
- diagnostic: better discrimination for lymph nodes and great vessels in mediastinum, better
analysis of the digestive structures with the injected CT scan;
- logistic: the 2 examinations, PET scan and injected CT scan, are performed in one time and
in the same unit;
- radioprotection: there is no need of low dose CT scan.
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